Possible role of autoantibodies in the pathophysiology of GM2 gangliosidoses

Journal of Clinical Investigation

Volumn 113, Issue 2, 2004, Pages 200-208

  Yamaguchi, Akira ^a   Katsuyama, Kayoko ^a   Nagahama, Kiyotaka ^a   Takai, Toshiyuki ^b   Aoki, Ichiro ^a   Yamanaka, Shoji ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GANGLIOSIDE GM2; GLYCOLIPID; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; GM2 GANGLIOSIDOSIS; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; MOUSE; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SANDHOFF DISEASE; ANIMAL; ANIMAL BEHAVIOR; APOPTOSIS; AUTOPSY; BLOOD BRAIN BARRIER; BRAIN; C57BL MOUSE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; HETEROZYGOTE; HUMAN; IMMUNOLOGY; INFANT; MALE; METABOLISM; NERVE CELL; NICK END LABELING; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TIME; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; AUTOANTIBODIES; AUTOPSY; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; G(M2) GANGLIOSIDE; GANGLIOSIDOSES, GM2; GLYCOLIPIDS; HETEROZYGOTE; HUMANS; IMMUNOGLOBULIN G; IN SITU NICK-END LABELING; INFANT; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; NEURONS; POLYMERASE CHAIN REACTION; SANDHOFF DISEASE; TIME FACTORS;

EID: 1342268315     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200419639     Document Type: Article

References (36)

1. Neufeld, E.F. 1991. Lysosomal storage diseases. Annu. Rev. Biochem. 60:257-280.
2. Gravel, R.A., et al. 2001. The GM2 gangliosidoses. In The metabolic and molecular basis of inherited disease. C.R. Scriver et al., editors. McGraw-Hill. New York, New York, USA. 3827-3876.
3. Yamanaka, S., Johnson, O.N., Norflus, F., Boles, D.J., and Proia, R.L. 1994. Structure and expression of the mouse beta-hexosaminidase genes, Hexa and Hexb. Genomics. 21:588-596.
4. Sango, K., et al. 1995. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat. Genet. 11:170-176.
5. Phaneuf, D., et al. 1996. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. Hum. Mol. Genet. 5:1-14.
6. Huang, J.Q., et al. 1997. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum. Mol. Genet. 6:1879-1885.
7. Norflus, F., et al. 1998. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J. Clin. Invest. 101:1881-1888.
8. Wada, R., Tifft, C.J., and Proia, R.L. 2000. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc. Natl. Acad. Sci. U. S. A. 97:10954-10959.
9. Myerowitz, R., et al. 2002. Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum. Mol. Genet. 11:1343-1350.
10. Jeyakumar, M., et al. 2003. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain. 126:974-987.
11. Yuki, N. 1999. Pathogenesis of Guillain-Barre and Miller Fisher syndromes subsequent to Campylobacter jejuni enteritis. Jpn. J. Infect. Dis. 52:99-105.
12. Niebroj-Dobosz, I., Jamrozik, Z., Janik, P., Hausmanowa-Petrusewicz, I., and Kwiecinski, H. 1999. Anti-neural antibodies in serum and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients. Acta Neurol. Scand. 100:238-243.
13. O'Hanlon, G.M., et al. 2000. Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: clinical and immunopathological studies. Autoimmunity. 32:133-144.
14. Takai, T., Li, M., Sylvestre, D., Clynes, R., and Ravetch, J.V. 1994. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 11:519-529.
15. Sango, K., Yamanaka, S., Ajiki, K., Tokashiki, A., and Watanabe, K. 2002. Lysosomal storage results in impaired survival but normal neurite outgrowth in dorsal root ganglion neurons from a mouse model of Sandhoff disease. Neuro. Pathol. Appl. Neurobiol. 28:1-17.
16. Tatematsu, M., et al. 1981. Sandhoff disease. Acta Pathol. Jpn. 31:503-512.
17. Taki, T., Nishiwaki, S., Ishii, K., and Handa, S. 1990. A simple and specific assay of glycosyltransferase and glycosidase activities by an enzyme-linked immunosorbent assay method, and its application to assay of galactosyltransferase activity in sera from patients with cancer. J. Biochem. (Tokyo). 107:493-498.
18. Bhattacharjee, A.K., Nagashima, T., Kondoh, T., and Tamaki, N. 2001. The effects of the Na(+)/Ca(++) exchange blocker on osmotic blood-brain barrier disruption. Brain Res. 11:157-162.
19. Rapoport, S.I., Fredericks, W.R., Ohno, K., and Pettigrew, K.D. 1980. Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am. J. Physiol. 238:R421-R431.
20. Yamaguchi, A., et al. 2003. Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease. J. Mol. Med. 81:185-193.
21. Neufeld, E.F., and Fratantoni, J.C. 1970. Inborn errors of mucopolysaccharide metabolism. Science. 169:141-146.
22. Yew, N.S., and Cheng, S.H. 2001. Gene therapy for lysosomal storage disorders. Curr. Opin. Mol. Ther. 3:399-406.
23. Bou-Gharios, G., Abraham, D., and Olsen, I. 1993. Lysosomal storage diseases: mechanisms of enzyme replacement therapy. Histochem. J. 25:593-605.
24. Walport, M.J. 2000. Lupus, DNase and defective disposal of cellular debris. Nat. Genet. 25:135-136.
25. Napirei, M., et al. 2000. Features of systemic lupus erythematosus in Dnase 1-deficient mice. Nat. Genet. 25:177-181.
26. Takai, T. 2002. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2:580-592.
27. Ravetch, J.V., and Bolland, S. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19:275-290.
28. Abdul-Majid, K.B., et al. 2002. Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scand. J. Immunol. 55:70-81.
29. Shinoda, S., et al. 2003. Formation of a tumour necrosis factor receptor 1 molecular scaffolding complex and activation of apoptosis signal-regulating kinase 1 during seizure-induced neuronal death. Eur. J. Neurosci. 17:2065-2076.
30. Yang, X., Khosravi-Far, R., Chang, H.Y., and Baltimore, D. 1997. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 27:1067-1076.
31. Marti, G.E., et al. 1988. Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. Am. J. Hematol. 29:189-194.
32. Mizukami, H., et al. 2002. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J. Clin. Invest. 109:1215-1221. doi:10.1172/JCI200214530.
33. Jeyakumar, M., et al. 2001. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood. 97:327-329.
34. Krivit, W., Peters, C., and Shapiro, E.G. 1999. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr. Opin. Neurol. 12:167-176.
35. Barton, N.W., et al. 1991. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 23:1464-1470.
36. Tifft, C.J., and Proia, R.L. 2000. Stemming the tide: glycosphingolipid synthesis inhibitors as therapy for storage diseases. Glycobiology. 10:1249-1258.